Advertisement

Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis

Abstract

Aims and background. The addition of trastuzumab to chemotherapy for HER2-positive metastatic breast cancer has significantly improved progression-free survival and overall survival, although most patients develop resistance or have a primarily resistant disease. The aim of the study was to describe the efficacy and safety of a firstline treatment in unselected metastatic HER2-positive breast cancer patients, treated according to clinical practice.
Methods. From 2000 to 2009, we conducted a retrospective multi-institutional analysis of 182 consecutive patients with HER2-positive metastatic breast cancer who underwent first-line treatment with trastuzumab. The primary end points were progression- free survival and overall survival; the secondary end points were survival after progression in patients treated with second-line chemotherapy with or without trastuzumab and safety. A total of 172 patients were analyzed.
Results. Median progression-free survival and overall survival were 1.2 (95% CI, 1.1- 1.4) and 4.4 years (95% CI, 3.6-5.4), respectively. For 100 patients who received second- line chemotherapy, median survival after progression was significantly longer in those who also received trastuzumab: 2.8 (95% CI, 2.1-4.0) versus 1.2 years (95% CI, 0.6-1.9).
Conclusions. Although based on retrospective data, the study confirms the role of trastuzumab as first-line treatment in metastatic breast cancer outside of a controlled trial. Moreover, information obtained on the use of trastuzumab beyond disease progression supports its use in this setting.

Tumori 2014; 100(4): 426 - 431

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1636.17902

Authors

Elena Collovà, Antonella Ferzi, Giuseppa Scandurra, Gaetano Aurilio, Valter Torri, Luca Porcu, Maria Vita Sanò, Eleonora Taibi, Jennifer Foglietta, Daniele Generali, Daniele Andreis, Maria Chiara Dazzani, Annalisa Bramati, Ilaria Marcon, Francesco Atzori, Saverio Cinieri, Luca Tondulli, Donatella Grasso, Franco Nolè, Maria Cristina Petrella, Stefania Gori, Nicla La Verde

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Collovà, Elena [PubMed] [Google Scholar]
    Ospedale Civile di Legnano, Department of Oncology, Legnano, Milan, Italy
  • Ferzi, Antonella [PubMed] [Google Scholar]
    Ospedale Civile di Legnano, Department of Oncology, Legnano, Milan, Italy
  • Scandurra, Giuseppa [PubMed] [Google Scholar]
    Azienda Ospedaliera Cannizzaro, Department of Oncology, Catania, Italy
  • Aurilio, Gaetano [PubMed] [Google Scholar]
    European Institute of Oncology, Department of Oncology, Milan, Italy
  • Torri, Valter [PubMed] [Google Scholar]
    “Mario Negri” Institute, Laboratory of Methodology for Biomedical Research, Milan, Italy
  • Porcu, Luca [PubMed] [Google Scholar]
    “Mario Negri” Institute, Laboratory of Methodology for Biomedical Research, Milan, Italy
  • Sanò, Maria Vita [PubMed] [Google Scholar]
    Humanitas Centro Catanese di Oncologia, Department of Oncology, Catania, Italy
  • Taibi, Eleonora [PubMed] [Google Scholar]
    Humanitas Centro Catanese di Oncologia, Department of Oncology, Catania, Italy
  • Foglietta, Jennifer [PubMed] [Google Scholar]
    Azienda Ospedaliera Perugia, Department of Oncology, S. Andrea delle Fratte, Perugia, Italy
  • Generali, Daniele [PubMed] [Google Scholar]
    Istituti Ospitalieri di Cremona, Department of Mammarian Pathology, Cremona, Italy
  • Andreis, Daniele [PubMed] [Google Scholar]
    Istituti Ospitalieri di Cremona, Department of Mammarian Pathology, Cremona, Italy
  • Dazzani, Maria Chiara [PubMed] [Google Scholar]
    Azienda Ospedaliera Fatebenefratelli e Oftalmico, Department of Oncology, Milan, Italy
  • Bramati, Annalisa [PubMed] [Google Scholar]
    Azienda Ospedaliera Fatebenefratelli e Oftalmico, Department of Oncology, Milan, Italy
  • Marcon, Ilaria [PubMed] [Google Scholar]
    Azienda Ospedaliera di Circolo e Fondazione Macchi, Department of Oncology, Varese, Italy
  • Atzori, Francesco [PubMed] [Google Scholar]
    University Hospital, Department of Oncology, bivio Sestu, Monserrato, Cagliari, Italy
  • Cinieri, Saverio [PubMed] [Google Scholar]
    Ospedale “A Perrino”, Department of Medical Oncology, Division & Breast Unit, Brindisi, Italy
  • Tondulli, Luca [PubMed] [Google Scholar]
    AO Maggiore, Department of Oncology, Verona, Italy
  • Grasso, Donatella [PubMed] [Google Scholar]
    IRCC Policlinico San Matteo, Department of Hematology and Oncology, Pavia, Italy
  • Nolè, Franco [PubMed] [Google Scholar]
    IRCC Policlinico San Matteo, Department of Hematology and Oncology, Pavia, Italy
  • Petrella, Maria Cristina [PubMed] [Google Scholar]
    Ospedale Unico della Versilia, Department of Oncology, Lido di Camaiore, Italy
  • Gori, Stefania [PubMed] [Google Scholar]
    Ospedale Sacro Cuore Don Calabria, Department of Oncology, Negrar (VR), Italy
  • Verde, Nicla La [PubMed] [Google Scholar]
    Azienda Ospedaliera Fatebenefratelli e Oftalmico, Department of Oncology, Milan, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.